



IDT Australia Ltd - Appointment of Director

*Global specialty product development expertise
Complements and builds upon recent senior management appointments
Demonstrates IDT's continuing development of a global specialty pharmaceuticals business*

8 October 2015, Melbourne: IDT Australia Limited (IDT) announces that **Mr. Hugh Burrill** has been appointed as a Director of the IDT Board, effective today.

Mr. Burrill has held a number of senior pharmaceutical industry executive roles, including Corporate Vice President, Global Pharma Research and Development for Hospira Inc., one of the top 10 generics companies globally. In this role he was responsible for overall pipeline portfolio management, and research and development of generic and specialty pharmaceuticals. Prior to this he held other senior international roles within Hospira and the original Mayne Pharma. He currently provides consulting services in the area of pharmaceutical strategic management, product development, regulatory affairs and intellectual property. Additionally he previously served as Managing Director of CCH Pharma Pty Ltd. Since 2007 he has been Non-Executive Director and Deputy Chair (July 2015) of Nova Aerospace Pty Ltd.

“We are extremely pleased to welcome Hugh to the Board of IDT and consider his deep knowledge of the global specialty pharmaceutical industry and extensive product development expertise will be invaluable to the ongoing development of IDT’s pharmaceutical product portfolio.” said IDT’s Chairman, Mr. Graeme Kaufman “In addition we welcome his input into future acquisitions and product pipeline opportunities to continue transformation of the Company into a specialty pharmaceuticals business.”

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based at the Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.